Atossa Genetics (ATOS) CEO Steve Quay on Preliminary Results from Male Phase 1 Study of Topical Endoxifen Conference (Transcript) [Seeking Alpha]
Atossa Therapeutics, Inc. (ATOS)
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.atossagenetics.com
Company Research
Source: Seeking Alpha
Atossa Genetics, Inc. (NASDAQ: ATOS ) Preliminary Results from Male Phase 1 Study of Topical Endoxifen Conference Call September 13, 2018 10:00 AM ET Executives Scott Gordon – President-CORE IR Kyle Guse – Chief Financial Officer, General Counsel and Secretary Steve Quay – Chairman and Chief Executive Officer Janet Rea – Senior Vice President, Regulatory, Quality and Clinical Affairs Analysts Operator Good day and welcome to the Atossa Genetics Conference Call to Discuss Preliminary Results from Atossa’s Male Phase 1 Study of Topical Endoxifen. All participants will be in a listen-only mode. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Scott Gordon, President of CORE IR, the Company's Investor Relations firm. Please go ahead, sir. Scott Gordon Thank you, Chad. And thank you for joining today's conference call to discuss Atossa Genetics Preliminary Results from Atossa’s Male Phase 1 Stud
Show less
Read more
Impact Snapshot
Event Time:
ATOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATOS alerts
High impacting Atossa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATOS
News
- Atossa Therapeutics Announces Support of New Breast Cancer Screening GuidelinesGlobeNewswire
- Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen [Yahoo! Finance]Yahoo! Finance
- Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-EndoxifenGlobeNewswire
- Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
- Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerGlobeNewswire
ATOS
Sec Filings
- 5/10/24 - Form ARS
- 5/10/24 - Form PRE
- 4/11/24 - Form 4
- ATOS's page on the SEC website